Culmerciclib in HR+/HER2+ Advanced Breast Cancer

计划入组 35 人 · 首次发布于 2026 年 7 月 29 日

HR+/HER2- Advanced Breast Cancer and Endocrine Resistance

计划入组 42 人 · 首次发布于 2017 年 10 月 26 日

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

计划入组 620 人 · 首次发布于 2022 年 10 月 26 日

Abemaciclib(Verzenio, Verzenios)

C₂₇H₃₂F₂N₈ · Rx

HER2+ Breast Cancer(Diakonos)

oncology program (HER2+ breast cancer)

JAPAN BREAST CANCER RESEARCH GROUP

Japan

ANZ BREAST CANCER TRIALS GROUP LIMITED

Australia

International Breast Cancer Research Foundation

United States

Sihuan Pharmaceutical's Bireociclib Receives NMPA Approval for First-Line HR+/HER2- Advanced Breast Cancer Treatment

Genentech's Inavolisib Receives FDA Approval for Advanced HR+, HER2- Breast Cancer

Gedatolisib Shows Promising 77-Month Overall Survival in Advanced Breast Cancer Phase 1b Trial